Cholangiocarcinoma

In this video, Lionel Aurelien Kankeu Fonkoua, MD, discusses the latest developments in targeted therapy options for cholangiocarcinoma.

Didn’t make it to the meeting? Here’s a collection of Healio-curated highlights, including expert insight on the latest research and treatments for biliary diseases, including primary biliary cholangitis, progressive familial cholestasis and more.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about research assessing the role of Claudin-1 in cholangiocarcinoma, which was presented at The Liver Meeting.

The FDA granted orphan drug designation to ZB131 for treatment of cholangiocarcinoma, according to the agent’s manufacturer.

The FDA granted accelerated approval to futibatinib for certain patients with cholangiocarcinoma.

The FDA granted priority review to futibatinib for treatment of certain patients with cholangiocarcinoma.

Rare Disease Day is Feb. 28.

The FDA granted orphan drug designation to silmitasertib for treatment of biliary tract cancer.

The FDA granted fast track designation to TT-00420 for treatment of patients with cholangiocarcinoma who have no standard therapy options.

The addition of durvalumab to standard first-line chemotherapy extended survival among patients with advanced biliary tract cancer, according to topline data released by the agent’s manufacturer.